6/12 Drugs.com - Clinical Trials

Please add updates@feedmyinbox.com to your address book to make sure you receive these messages in the future. Drugs.com - Clinical Trials MabThera reduces progression of joint damage in rheumatoid arthritis when used as a first-line biologic June 11, 2009 at 4:50 pm New data demonstrate the ability of MabThera to reduce the progression of joint damage when used as a first-line biologic treatment in rheumatoid arthritis RA patients with enhanced response identified Basel, 11 June 2009 -- New data show for the... New Phase 3 Data Continue to Indicate that Wyeth's Investigational 13-valent Vaccine Has the Potential to Broaden Coverage Against Pneumococcal Disease June 11, 2009 at 4:47 pm COLLEGEVILLE, Pa., June 11 /PRNewswire-FirstCall/ -- New data from Phase 3 European clinical trials reinforce that Wyeth's (NYSE:WYE) investigational pneumococcal vaccine, Prevenar 13* (Pneumococcal Polysaccharide Conjugate Vaccine, 13-valent... Pfizer's Oral JAK-3 Inhibitor Demonstrates Statistically Significant Response For Patients with Rheumatoid Arthritis, New Phase 2 Studies Show June 11, 2009 at 4:32 pm Global Phase 3 Clinical Program Enrolling Patients COPENHAGEN--(BUSINESS WIRE)--Jun 11, 2009 - Pfizer announced today that data from two new mid-stage clinical studies of the company's oral JAK-3 inhibitor, CP-690,550, showed statistically... Neurim Pharmaceuticals Reports Long Term Efficacy and Safety for Circadin for Insomnia in Elderly Patients June 11, 2009 at 4:20 pm SEATTLE, June 11/PRNewswire/ -- Neurim Pharmaceuticals (http://www.neurim.com) presented today the preliminary results of a large-scale Phase III study of Circadin(R) 2mg, prolonged release melatonin in insomnia, demonstrating long term efficacy and... Cannabis Science: Can Cannabis-Based Drugs Slow the H1N1 "Swine Flu" Pandemic? June 11, 2009 at 4:14 pm SAN FRANCISCO--(BUSINESS WIRE)--Jun 11, 2009 - The World Health Organization declared a swine flu pandemic Thursday, raising its pandemic warning from phase 5 to 6, making swine flu the first global flu epidemic in 41 years. Now that H1N1 "Swine... Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis-C Virus (HCV) June 11, 2009 at 4:05 pm SAN DIEGO, June 10 /PRNewswire-FirstCall/ -- Aethlon Medical, Inc., (OTC Bulletin Board: AEMD) disclosed today that its Chairman and CEO, James A. Joyce has issued the following letter to... Data Demonstrated ACTEMRA (tocilizumab) Significantly Inhibited Progression of Structural Joint Damage in Rheumatoid Arthritis Patients June 11, 2009 at 3:59 pm - Additional data reinforce long-term efficacy of ACTEMRA across a broad range of rheumatoid arthritis patient populations - NUTLEY, N.J., June 10 /PRNewswire/ -- One-year data from the two-year Phase III LITHE (TociLIzumab Safety and THE Prevention... Enobia Announces Positive Interim Clinical Results with ENB-0040 June 11, 2009 at 3:45 pm MONTREAL, June 11 /CNW Telbec/ - Enobia Pharma, an emerging biotech company focused on developing novel therapeutics for serious bone disorders, announced that results from two early-stage studies of the company's lead product, ENB-0040, were... Overview of Pixantrone Phase III Clinical Data Presentation at American Society of Clinical Oncology 2009 Annual Meeting Now Available at Clinical Care Options June 11, 2009 at 3:00 pm SEATTLE, June 10 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. ("CTI") (Nasdaq and MTA: CTIC) announced today that a summary of the pixantrone Phase III clinical data that were presented at American Society of Clinical Oncology (ASCO) 2009... New Data on Once-Daily Extended Release Pramipexole Presented at 13th International Congress of Parkinson's Disease and Movement Disorders (MDS) June 11, 2009 at 2:35 pm Data indicates pramipexole extended release is comparable to the immediate release formulation PARIS--(BUSINESS WIRE)--Jun 10, 2009 - New data presented today at the Movement Disorder Society's 13th International Congress of Parkinson's Disease and... GTx Presents Phase II Ostarine (MK-2866) Cancer Cachexia Clinical Trial Results at Endocrine Society Annual Meeting June 11, 2009 at 2:31 pm Ostarine Improved Lean Body Mass and Muscle Performance in Patients with Cancer Cachexia WASHINGTON--(BUSINESS WIRE)--Jun 11, 2009 - GTx, Inc. (Nasdaq: GTXI) today announced results of a Phase II clinical trial evaluating Ostarine™ (MK-2866),... Sanofi-aventis and Regeneron Announce Results from Phase 2 Study with Aflibercept (VEGF Trap) in Advanced Ovarian Cancer Patients with Recurrent Symptomatic Malignant Ascites June 11, 2009 at 2:31 pm PARIS & TARRYTOWN, N.Y.--(BUSINESS WIRE)--Jun 11, 2009 - Sanofi-aventis (Euronext: SAN and NYSE: SNY) and Regeneron Pharmaceuticals, Inc. (Nasdaq: REGN) today announced that advanced ovarian cancer patients with recurrent symptomatic malignant... Human Genome Sciences Reports Positive Long-Term Data For Benlysta (Formerly Lymphostat-B) In Patients With Active Systemic Lupus Erythematosus June 11, 2009 at 11:07 am - Phase 2 continuation data demonstrated sustained improvement in disease activity and patient response rate through four years of BENLYSTA therapy - - Frequency of disease flares as measured by the SELENA SLEDAI flare index and by BILAG A or B... Ardea Biosciences Announces Positive Interim Phase 2a Results for Lead Gout Drug, RDEA594 June 11, 2009 at 10:58 am 86% Response Rate in Gout Patients After Eight Days of Treatment SAN DIEGO--(BUSINESS WIRE)--Jun 11, 2009 - Ardea Biosciences, Inc. (Nasdaq:RDEA) today announced positive interim results from an ongoing Phase 2a, proof-of-concept study of RDEA594,... New Versartis Data Demonstrates Potential for Monthly Dosing June 11, 2009 at 10:02 am New Company Focusing on Extending Half-Life of Drugs for Metabolic and Endocrine Diseases WASHINGTON--(Marketwire - June 10, 2009) - Versartis, Inc., an emerging company developing novel biologics with enhanced properties for patients with metabolic... HRV phase IIa study achieves clinical proof-of-concept June 11, 2009 at 9:51 am Melbourne, Australia — 11 June 2009 HRV phase IIa study achieves clinical proof-of-concept Biota Holdings Limited (ASX:BTA) announced today that its Phase IIa challenge study of BTA798, an orally active inhibitor of human rhinovirus (HRV), was... Genetic Variant Associated With Resistance To Chemotherapy Drug In Women With Breast Cancer June 11, 2009 at 9:01 am BETHESDA, Md., June 9, 2009--Researchers have found links between an individual's genetics and their response to treatment with chemotherapy. The findings, by researchers at the National Cancer Institute (NCI), part of the National Institutes of... Human Genome Sciences Reports Positive Long-Term Data for BENLYSTA (Formerly LymphoStat-B) in Patients With Active Systemic Lupus Erythematosus June 11, 2009 at 8:36 am - Phase 2 continuation data demonstrated sustained improvement in disease activity and patient response rate through four years of BENLYSTA therapy - - Frequency of disease flares as measured by the SELENA SLEDAI flare index and by BILAG A or B... Aradigm Presents Phase 1 and Phase 2 Data on Inhaled Liposomal Ciprofloxacin in Healthy Volunteers and Cystic Fibrosis Patients at the 32nd European Cystic Fibrosis Conference June 11, 2009 at 8:15 am Both Studies Demonstrated Pharmacokinetics Supporting Once-Daily Dosing, with Significant Reduction in Bacterial Infection in Cystic Fibrosis Patients HAYWARD, Calif.--(BUSINESS WIRE)--Jun 11, 2009 - Aradigm Corporation (OTCBB:ARDM) ("Aradigm")... Two-Year Data Show Patients Receiving Simponi (golimumab) Experienced Sustained Improvement in Signs and Symptoms of Psoriatic Arthritis and Ankylosing Spondylitis June 10, 2009 at 5:03 pm Long-Term Data in Patients Receiving Every-Four-Week Subcutaneous SIMPONI Presented at 2009 EULAR Annual Congress COPENHAGEN, June 9 /PRNewswire/ -- Findings from open-labeled, uncontrolled extensions of two randomized, placebo-controlled Phase 3... Newly Analyzed Data Show Daily Treatment With Nasonex Significantly Reduces Symptom Recurrence In Patients With Perennial Allergic Rhinitis June 10, 2009 at 5:02 pm Warsaw, Poland – June 9, 2009 – Recently analyzed data demonstrate the benefits of adhering to a daily NASONEX® (mometasone furoate monohydrate) Nasal Spray, 50 mcg* treatment regimen following initial symptom relief, including... New Analysis Shows Efficacy of Simponi (golimumab) in Anti-TNF Experienced Rheumatoid Arthritis Patients June 10, 2009 at 4:56 pm Anti-TNF Experienced Patients Demonstrated Improvement With Every-Four-Week Subcutaneous SIMPONI Despite Previous Medication or Reason for Discontinuation COPENHAGEN, June 9 /PRNewswire/ -- A new analysis demonstrated that a greater proportion of... Starting Antiretroviral Therapy Earlier Yields Better Clinical Outcomes June 10, 2009 at 4:41 pm Review Leads to Early End of Clinical Trial in Haiti BETHESDA, Md., June 9, 2009--A clinical trial has demonstrated that HIV-infected adults in a resource-limited setting are more likely to survive if they start antiretroviral therapy (ART) before... Data Demonstrate Aerius® (Desloratadine) Reduces Symptoms And Improves Quality Of Life In Patients With Persistent Allergic Rhinitis June 10, 2009 at 4:33 pm Analyses evaluate the relationship between symptom improvement of ARIA-defined persistent allergic rhinitis and daily functioning   Warsaw, Poland – June 9, 2009 – AERIUS® (desloratadine) significantly reduces the impact of... New Analyses Show Nasonex Is More Effective Than Loratadine For The Treatment Of Nasal Allergy Symptoms And At Least Comparable For Ocular Symptoms June 10, 2009 at 4:28 pm Warsaw, Poland – June 9, 2009 – According to new data presented today for the first time, patients with seasonal allergic rhinitis (SAR) experienced greater relief of nasal symptoms and equivalent relief of ocular symptoms with... Juvista European Phase 2 clinical trial June 10, 2009 at 4:13 pm POSITIVE 12 MONTH ANALYSIS OF JUVISTA® MULTI-CENTRE PHASE 2 EUROPEAN TRIAL IN VARICOSE VEIN SURGERY LONDON, 9 June 2009--Renovo Group plc (LSE: RNVO), the biopharmaceutical company developing drugs for the reduction of scarring, is pleased to...   This email was sent to skripayura.drugsnews@blogger.com.  Create Your Account Don't want to receive this feed any longer? Unsubscribe here.